• 3 April 2018

    Axonics Modulation Technologies, Inc., a privately-held developer of the first rechargeable Sacral Neuromodulation (r-SNM™) system for the treatment of urinary and bowel dysfunction, announced today that it has completed a $40.1 million financing that combines $20.1 million in equity and a $20 million credit facility.

  • 28 March 2018

    Wilson Therapeutics AB (publ), announced today that preliminary long-term efficacy and safety data from the ongoing extension phase of the company’s Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper-protein-binding agent under investigation as a novel therapy for Wilson Disease, has been accepted as a late-breaker poster presentation at The International Liver Congress™ 2018, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Paris, France, 11-15 April, 2018.

  • 28 March 2018

    InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod will be issued by the Japan Patent Office. The patent provides additional protection for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy, wherein cobitolimod is not administered in combination with corticosteroid or glucocorticosteroid.

  • 23 March 2018

    JenaValve Technology, Inc., a developer, manufacturer and marketer of differentiated transcatheter aortic valve replacement (TAVR) systems for the treatment of aortic valve disease, today announced the appointment of veteran medical device executive Keith D. Dawkins, M.D., as a new JenaValve board member. 

  • 22 March 2018

    Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the appointment of Caroline Van Hove as the Company’s first Chief Commercial Officer. Ms. Van Hove will develop, lead and have overall responsibility for Sienna’s commercial strategy and operations. Sienna currently has five clinical-stage programs in development from the Company’s Topical by Design™ and Topical Photoparticle Therapy™ platforms.